The collaborative goal of the Viromed and the Terraplasma is to forge together a world’s leading company and to be the eminent innovators for developing medical technologies infused with cold atmospheric plasma in a wider range.
Cold atmospheric plasma is highly efficient in inactivating bacteria, multi-resistant pathogens including viruses and fungi both physically and chemically. Therefore, its application in medical technology can revolutionise and, in some cases, replace the conventional treatment methodologies. For instance, Cold plasma can be used to prevent infections in the post-surgical wounds. Therapeutically, cold atmospheric plasma could be a better option for nursing chronic, long-standing, and non-healing wounds. Treatments using cold plasma reduces the antibiotic and cortisone usage. Moreover, it neither causes an allergic side effect nor pain. To make use of this wonderful capability of cold plasma, The plasma care® product line developed by terraplasma medical GmbH, will be subjected to a further expansion in the future.
Lower drug usage and lesser resistance:
In recent years, the clinical observations revealed that this new therapy using cold plasma has not only effective in bactericidal and wound-healing property but also in reducing the nursing and dressing costs of the wounds. In addition, it has also been proven to reduce the post operative complications and longer hospital stays. With the reduction in the usage of antibiotics, the emergence and prevalence of resulting drug resistance is prevented, and only fewer anti-inflammatory drugs could be administered in dermatology. Lastly, Cold plasma on successful therapy could be used to treat the wounds on the legs of a diabetic patient and open sores in the legs.
“With the new beginning of Viromed and Terraplasma medical, the existing and successful cooperation would be appreciably made stronger and expanded especially, in the broad marketing of the plasma care® product range”, says Uwe Perbandt. The Perbandt family holds the ownership of Viromed Group through its holding company, Perbamed Invest GmbH.
Jens Kirsch, CEO of Terraplasma medical, is extremely pleased to acquire the strong sales and financial support and partnership in the Viromed Group. Similarly, Julia Zimmermann, CEO of Terraplasma, is very positive and enthusiastic about continuing in developing innovative medical solutions with Terraplasma medical and successfully establishing in the market.
“The retiring shareholders of the investor group in Kuenheim Familiaris are proud to have accompanied such a successful company development,” says Fabian von Kuenheim.
Immense support from Max Planck Innovation:
The Max Planck Innovation, the pivotal organisation for technology transfer in the Max Planck Society, has enormously supported Terraplasma from its starting stages, specifically in consulting, patenting of research results, licensing and as representative of shareholder. “We are pleased with the Max Planck spin-off terraplasma about the great success with the subsidiary of terraplasma medical in which, among other things, findings from the basic research on cold plasma at the Max Planck Institute for Extraterrestrial Physics have already been successfully transferred to patient applications. We wish terraplasma and its new strong partner Viromed Plasma every success in the development and introduction of new products from terraplasma medical for many other medical applications,” says Ulrich Mahr, member of the management board of Max Planck Innovation.
